This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	RAB11 family interacting protein 1 (RAB11FIP1; RCP)	<i>In vitro</i> and mouse studies suggest that inhibiting RCP could help treat breast cancer. RCP is overexpressed in human breast cancers. In mice xenografts, breast cancer cells with RCP knockdown showed less tumor formation and metastasis than breast cancer cells expressing the protein. Next steps include determining whether RCP can be targeted by RCP-specific antibodies. Concordia Pharmaceuticals Inc. has salirasib, a Ras antagonist, in clinical testing for various cancers. <i>SciBX</i> 2(29); doi:10.1038/scibx.2009.1137 Published online July 30, 2009	Patent application filed; available for licensing	Zhang, J. <i>et al.</i> <i>J. Clin. Invest.</i> ; published online July 20, 2009; doi:10.1172/JCI37622 Contact: Lance David Miller, Wake Forest University School of Medicine, Winston-Salem, N.C. e-mail: ldmiller@wfubmc.edu Contact: Bing Lim, Genome Institute of Singapore, Singapore e-mail: limb1@gis.a-star.edu.sg